A sterile compounding pharmacy prepares medications in a contamination-free environment using aseptic techniques, ensuring every product is free of microorganisms before it reaches a patient. These pharmacies primarily produce injectable drugs, IV infusions, eye drops, and implantable preparations, all of which bypass the body’s natural defenses and must be completely sterile to be safe. The work happens in specially designed cleanrooms under strict regulatory standards that go far beyond what a typical pharmacy requires.
Why Sterile Compounding Exists
Not every medication a patient needs is available off the shelf. Sometimes a commercially manufactured drug is on backorder or discontinued entirely. Other times, a patient needs a specific dose, combination, or formulation that no manufacturer produces. A child may need a lower-concentration injectable, or a patient with an allergy may need a preservative-free version of a standard drug. In these cases, a sterile compounding pharmacy can prepare a custom product based on a prescriber’s order.
The formal definition from the United States Pharmacopeia describes compounding as “the preparation, mixing, assembling, altering, packaging, and labeling of a drug, drug-delivery device, or device in accordance with a licensed practitioner’s prescription, medication order, or initiative based on the practitioner-patient-pharmacist-compounder relationship.” When that preparation needs to be sterile, the entire process must happen in a controlled environment with rigorous contamination safeguards.
How It Differs From Non-Sterile Compounding
Non-sterile compounding covers things like custom-flavored oral suspensions, topical creams, and capsules. These are prepared on clean workbenches but don’t require the same level of environmental control because they’re applied to the skin or taken by mouth, where the body has natural barriers against contamination.
Sterile compounding is a different level entirely. Injectables go directly into the bloodstream, and eye drops contact tissue with almost no immune defense. A single bacterium or fungal spore in an injectable product can cause a life-threatening infection. That’s why sterile compounding requires cleanroom facilities, specialized air filtration, gowning procedures, and ongoing environmental monitoring that non-sterile compounding does not.
Inside the Cleanroom
Sterile compounding happens in rooms classified by how many airborne particles they allow per cubic meter. The actual compounding surface, where a pharmacist handles vials and syringes, must meet ISO Class 5 standards, meaning the air contains virtually no particles. This workspace sits inside a buffer room rated at ISO Class 7, which serves as a controlled zone with filtered air and restricted access. Many facilities also include an anteroom rated at ISO Class 8, where staff change into cleanroom garments before entering the buffer area.
Air handling is critical. The buffer room must cycle its air at least 20 times per hour through HEPA filters that trap 99.97% of particles. Pressure differentials between rooms are checked daily before production begins, ensuring air flows outward from the cleanest areas to prevent contamination from drifting in. Particle counts and viable air sampling (testing for living microorganisms) are conducted regularly, with strict limits on how many colonies of bacteria or fungi are acceptable. At the ISO Class 5 compounding surface, the action level is just 3 colony-forming units. Anything above that triggers an investigation.
Gowning and Personnel Requirements
Before entering the cleanroom, staff follow a precise gowning sequence designed to cover the body from the “dirtiest” areas to the “cleanest.” They first remove all personal outer garments, jewelry, cosmetics, and artificial nails. Then they put on dedicated shoe covers, followed by head and facial hair covers, then a face mask and eye shield. After performing a thorough hand hygiene procedure, they don a nonshedding gown. Once inside the buffer area, they complete an antiseptic hand scrub and pull on sterile, powder-free gloves.
The training requirements are equally rigorous. Before being allowed to compound, each person must pass competency evaluations that include media-fill testing, which simulates the compounding process using a growth medium instead of actual drug ingredients. If any contamination shows up, the test is a failure. Staff must also pass a gloved fingertip sampling test, showing zero colony-forming units on all fingers of both hands, at least three times before they’re cleared to work. These competencies are revalidated every 12 months for personnel working with sterile ingredients, and every 6 months for those compounding from non-sterile starting materials.
Two Regulatory Pathways: 503A and 503B
Federal law creates two distinct categories of compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional pharmacies, where a licensed pharmacist compounds medications based on individual patient prescriptions. These pharmacies are primarily regulated by state boards of pharmacy and are exempt from FDA manufacturing requirements as long as they meet all the conditions of 503A.
Section 503B covers outsourcing facilities, a category created after a 2012 contaminated steroid injection outbreak killed dozens of people. Outsourcing facilities can compound medications without patient-specific prescriptions, essentially producing larger batches for hospitals and clinics. In exchange for that flexibility, they face tighter federal oversight. They must register with the FDA, submit to regular inspections, and report adverse events. Unlike 503A pharmacies, outsourcing facilities are not exempt from current good manufacturing practice requirements, meaning they operate closer to the standards expected of drug manufacturers.
The distinction matters for patients because it affects where your compounded medication comes from and what level of oversight went into making it. Hospital pharmacies typically compound under 503A for their own patients, while outsourcing facilities supply products to multiple healthcare settings.
What Gets Made in a Sterile Compounding Pharmacy
The most common products include IV bags with customized drug concentrations, injectable medications in prefilled syringes, preservative-free eye drops, and epidural or intrathecal injections used for pain management. Some sterile compounding pharmacies also prepare total parenteral nutrition (TPN), which delivers all of a patient’s nutritional needs directly into the bloodstream when they can’t eat. Others prepare chemotherapy infusions tailored to a patient’s specific weight and treatment protocol.
Each of these products has an expiration window called a beyond-use date, which is typically much shorter than what you’d see on a commercially manufactured drug. The exact timeframe depends on the category of the preparation, the sterility testing performed, and storage conditions. Products compounded under simpler conditions with fewer manipulations generally have shorter beyond-use dates, sometimes as little as hours at room temperature. More complex preparations made in fully certified cleanroom suites, with supporting sterility data, can have longer windows.
Why Quality Control Is Nonnegotiable
The stakes in sterile compounding are uniquely high. A contaminated oral medication might cause an upset stomach. A contaminated injectable can cause sepsis, meningitis, or death. Environmental monitoring provides the ongoing proof that the cleanroom is performing as intended. Viable air sampling tests whether living organisms are present in the air. Surface sampling checks countertops, walls, and equipment for microbial growth. These tests happen monthly under current USP standards, a significant increase from the previous requirement of every six months.
Pressure differentials between rooms are verified daily before any compounding begins, confirming that clean air is flowing in the right direction. All primary and secondary engineering controls, the hoods, isolators, and rooms themselves, must be certified on a regular schedule to confirm they still meet their ISO classification. When any monitoring result exceeds action levels, the pharmacy must investigate the cause, potentially discard affected products, and take corrective action before resuming compounding.